-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Immune escape is one of the key processes involved in tumor development, which is achieved by inducing and collecting multiple immunosuppressive cells and improving multiple immunosuppressive molecules.
, blocking this immunosuppression can restore the body's potential anti-tumor immune response.
studies have shown that programmed cell death protein 1 (PD-1) blocking therapy has clinical efficacy and can be quantified by PD-1-CD8-T cells in tumor micro-environment (TME).
August 31, 2020, the journal Nature-Immunology published the latest results of the Hiroyoshi Nishikawa Research Group of the Department of Medical Research, Nagoya University, Japan, entitled "The PD-1 Expressionbalance effector and regulatory cell T-predicts the clinical efficacyof PD-1 blockaderapies".
study, it is suggested that the PD-1 expression balance between effect and regulatory T-cells (Treg) can predict the clinical efficacy of PD-1 blocking therapy.
DOI:10.1038/s41590-020-0769-3 Researchers tested TILs using fluid cytometics (FCM) and found that patients treated with PD-1 blocking therapy had higher PD-1-CD8-T cell immersion in TME.
, CD8-T cells with high expression PD-1 have antigen peptides with high affinity.
contrary, PD-1 high expression in TME in patients with ineffective PD-1 blocking therapy was found in eTreg cells.
FCM analysis TILs used anti-PD-1 monoclonal antibodies to block PD-1, the TCR and CD28 signals of CD8-T cells and Treg cells were enhanced, and the immunosuppression of PD-1-eTreg cells was enhanced.
, the researchers believe that PD-1-Treg cells in TME are involved in resistance to PD-1 blocking therapy.
PD-1 monoclonal antibody therapy enhances the immune response researchers further suggest that the PD-1 expression balance of T-cells in TME is related to the body's response to PD-1 blocking, and that PD-1 monoantigen therapy can improve the survival rate of immunodeficiency mice with hormone tumors.
researchers analyzed T-cells in TME in patients with non-small cell lung cancer, stomach cancer, and malignant melanoma and found significant differences in the ratio of PD-1-CD8-T cells/PD-1-Treg cells in patients with PD-1 mono-antitherapy effective (R) and ineffective (NR).
of T-cell PD-1 expression in patients with TME, treatment with PD-1 monoclonal antibodies can improve TCR and CD28 signal release and reactivate PD-1-Treg cells.
explains the role of PD-1-Treg cells in PD-1 blocking therapy.
, the researchers believe that the PD-1 expression of PD-1-CD8-T cells/PD-1-Treg cells can predict the efficacy of PD-1 blocking therapy.
addition, PD-1-Treg cells in TILs can be used as targets for clinical treatment, and further studies may be available for clinical application.
references: s1. The PD-1 expression balance between effector and regulatory T cells predicts theclinical efficacy of PD-1 blockade therapies.